- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001656
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics
The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses.
Childhood psychosis is a serious disorder that may have devastating consequences. Effective treatments for the condition are under continual investigation. This study will examine the causes of and offer treatment for childhood psychosis.
Participants in this study will undergo psychological tests, blood and urine tests, electroencephalogram (EEG), electrocardiogram (EKG), and magnetic resonance imaging (MRI) scans of the brain for the first 1 to 2 weeks of the study while taking their regular medications. Participants will then be tapered off their medications over 1 to 3 weeks and will continue to stay off medications for an additional 2 days to 3 weeks. During this time, participants will undergo psychiatric, neurological, and cardiac examinations as well as blood tests. After this period without medications, participants will be randomly assigned to receive either clozapine or olanzapine for 8 weeks. An EEG will be performed prior to treatment and after 6 weeks of study medication. Participants who respond well to the study drugs may continue to receive them through their own physician. Participants who do not respond to either clozapine or olanzapine or cannot tolerate their side effects will be treated individually with other drugs until optimum treatment is identified. Regular telephone updates and in person visits to NIH for repeat testing and MRIs will be conducted.
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this protocol is to compare efficacy of clozapine and olanzapine in children and adolescents with schizophrenia and psychoses, as well as to learn about side effects of these medication in pediatric population. The underlying hypothesis is that clozapine has superior efficacy over olanzapine.
Children and adolescents, ages 7 to 18 years, meeting DSM-IV criteria for schizophrenia, schizoaffective disorder and psychotic disorder not otherwise specified, with onset of psychosis before their 13th birthday, who have not responded to at least two prior trials with typical or a typical neuroleptics, will be eligible to participate in a double-blind, parallel group, trial of olanzapine-clozapine.
This study will be done in conjunction with the Screening protocol, which will include characterization by clinical phenomenology, eye tracking, MRI brain imaging, plasma biochemistry, and chromosomal analysis.
This study will consist of the following phases 1) Tapering of psychotropic medications (1-4 weeks, depending upon type and dosage). 2) Observation for up to 2 weeks drug free, in order to establish a baseline prior to starting medication trial. 3) An 8 week double-blind trial of either clozapine or olanzapine. Efficacy and tolerability of clozapine and olanzapine will be compared using specified criteria. 4) If desired improvement not achieved or trial is interrupted, an 8 week open trial of the second medication and 5) Discharge following medication optimization for up to 4 weeks, or as clinically appropriate. This protocol also includes a follow-up every 2 to 3 years for a period of 10 years.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Males and females, age 7 to 18 years
Onset of psychotic symptoms before 13th birthday and a DSM-IV diagnosis of either schizophrenia, schizoaffective disorder, MDI syndrome, or psychosis NOS (not otherwise specified).
Current significant impairment due to the illness (current psychotic symptoms, decline of functioning academically and socially, significant discomfort due to psychotic symptoms).
Failure of two prior trials with antipsychotic medications (either typical or atypical) used at adequate doses (greater than or equal to 100 mg/day in chlorpromazine equivalents) and for adequate duration (at least 4 weeks, unless terminated due to intolerable side effects). Failure is defined as either insufficient response with persistence of symptoms significantly impairing child's functioning, according to child's and parental reports and medical and school records, or intolerable side effects to drugs other than clozapine and olanzapine.
Subjects may be included if their previous trial(s) of olanzapine failed to reach the dose of 20. mg/day or a duration of fewer than four weeks.
Subjects may be included if their previous trial(s) of clozapine failed to reach the dose of 200. mg/day or a duration of fewer than six weeks.
Comorbid psychiatric disorders in the past 12 months are permitted as long as not clinically significant.
EXCLUSION CRITERIA:
Prepsychotic full-scale IQ less than 70.
Unstable major neurological or medical conditions.
Current pregnancy or plan to become pregnant during the first three months (the duration of the study) in woman of childbearing age; breast-feeding in woman with infants.
DSM-IV substance abuse or dependence in the past 6 months.
True non-responders to either olanzapine or clozapine. True non-response is defined as: a) intolerance to either of the medications preventing an adequate trial, or b) only minimal (less than 20%) benefit with the adequate trial of either of the medications. Adequate trial constitutes at least 8 weeks of the medication with the dose of 20 mg on olanzapine or 200 mg of clozapine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Olanzapine
|
tablet; 5-20mg/day; 8 weeks
Other Names:
|
Active Comparator: Clozapine
|
tablet; 12.5-900mg/day; 8 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Scale for the Assessment of Negative Symptoms
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome
|
8 week double-blind study period; baseline and 8 weeks
|
Change in the Clinical Global Impression Severity of Symptoms Scale
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in the severity of symptoms; Minimum score = 1; maximum score = 7; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Change in the Brief Psychiatric Rating Scale-24
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
A 24-item scale measuring change in interpersonal behaviors, mood, psychosis, anxiety, speech, sleep, orientation and physical activity.
Lowest score = 24; highest score = 168; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Change in the Scale for the Assessment of Positive Symptoms
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in hallucinations, delusions, bizarre behavior, and thought organization.
Minimum score = 0; maximum score = 170; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Change in the Bunney-Hamburg Rating Scale for Psychosis
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in psychosis severity; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Change in Bunney-Hamburg Rating Scale for Depression
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in severity of depression; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Change in Bunney-Hamburg Rating Scale for Mania
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in the severity of mania; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Change in the Bunney-Hamburg Rating Scale for Anxiety
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
Measures change in the severity of anxiety; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
|
8 week double-blind study period; baseline and 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Weight
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
8 week double-blind study period; baseline and 8 weeks
|
|
Change in Body Mass Index (BMI)
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
BMI is calculated by the following formula: weight (in kilograms) divided by the square of the height (in meters)
|
8 week double-blind study period; baseline and 8 weeks
|
Change in Extrapyramidal Movements as Measured by the Abnormal Involuntary Movements Scale (AIMS)
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
minimum score = 10; maximum score = 50; lower score is considered a more favorable outcome
|
8 week double-blind study period; baseline and 8 weeks
|
Change in Extrapyramidal Movements as Measured by the Simpson Angus Scale Score
Time Frame: 8 week double-blind study period; baseline and 8 weeks
|
minimum score = 10; maximum score = 90; lower score considered a more favorable outcome
|
8 week double-blind study period; baseline and 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Judith L Rapoport, M.D., Child Psychiatry Branch, NIMH, NIH
Publications and helpful links
General Publications
- Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, Albus KE, et al. Childhood-onset schizophrenia: an NIMH study in progress. Schizophr Bull. 1994;20(4):697-712. doi: 10.1093/schbul/20.4.697.
- Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry. 1999 Nov 15;46(10):1418-28. doi: 10.1016/s0006-3223(99)00231-0.
- Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006 Jul;63(7):721-30. doi: 10.1001/archpsyc.63.7.721.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Schizophrenia Spectrum and Other Psychotic Disorders
- Neurodevelopmental Disorders
- Schizophrenia
- Disease
- Psychotic Disorders
- Mental Disorders
- Schizophrenia, Childhood
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Serotonin Antagonists
- GABA Agents
- GABA Antagonists
- Olanzapine
- Clozapine
Other Study ID Numbers
- 970126
- 97-M-0126
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Centre for Addiction and Mental HealthNot yet recruitingSchizophrenia | Schizophreniform DisordersCanada
-
Lithuanian University of Health SciencesRecruitingSchizophrenia | Cognitive Deficit | Negative Symptoms in Schizophrenia | Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)Lithuania
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
University Hospital, GrenobleNot yet recruitingSchizophrenia | Schizophrenia Schizoaffective
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Bradley LegaNot yet recruiting
-
New York State Psychiatric InstituteNot yet recruitingDepression | PTSD | Anxiety | Intimate Partner Violence
-
Teva Branded Pharmaceutical Products R&D, Inc.Not yet recruiting
-
University of California, San DiegoCentre for Addiction and Mental HealthNot yet recruitingSchizophrenia | Schizoaffective DisorderCanada, United States
Clinical Trials on Olanzapine
-
Teva Branded Pharmaceutical Products R&D, Inc.Not yet recruiting
-
Centre for Addiction and Mental HealthRecruitingInsulin Resistance | Type 2 Diabetes | Menstrual Cycle | AntipsychoticsCanada
-
M.D. Anderson Cancer CenterNot yet recruiting
-
The Royal Ottawa Mental Health CentreThe Royal's Institute of Mental Health ResearchRecruitingSchizophrenia | Schizoaffective DisorderCanada
-
Icahn School of Medicine at Mount SinaiRecruitingPsychological Distress | Suicide Crisis SyndromeUnited States
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Simon Williamson ClinicHelsinn Healthcare SARecruitingChemotherapy Induced Nausea and VomitingUnited States
-
University Hospital, Basel, SwitzerlandRecruiting
-
Christian HassagerRecruitingOut-Of-Hospital Cardiac Arrest | Post-Cardiac Arrest SyndromeDenmark
-
Alexandria UniversityRecruitingSubstance Use Disorders | Substance DependenceEgypt